Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMCQF) Raw Materials (2016 - 2025)

Fresenius Medical Care AG has reported Raw Materials over the past 17 years, most recently at $383.3 million for Q4 2025.

  • Quarterly results put Raw Materials at $383.3 million for Q4 2025, up 4.18% from a year ago — trailing twelve months through Dec 2025 was $383.3 million (up 4.18% YoY), and the annual figure for FY2025 was $383.3 million, up 4.18%.
  • Raw Materials for Q4 2025 was $383.3 million at Fresenius Medical Care AG, up from $367.9 million in the prior quarter.
  • Over the last five years, Raw Materials for FMCQF hit a ceiling of $517.2 million in Q4 2021 and a floor of $313.2 million in Q4 2022.
  • Median Raw Materials over the past 5 years was $383.3 million (2025), compared with a mean of $394.2 million.
  • Biggest five-year swings in Raw Materials: skyrocketed 86.62% in 2021 and later crashed 39.44% in 2022.
  • Fresenius Medical Care AG's Raw Materials stood at $517.2 million in 2021, then tumbled by 39.44% to $313.2 million in 2022, then grew by 24.29% to $389.3 million in 2023, then dropped by 5.48% to $367.9 million in 2024, then increased by 4.18% to $383.3 million in 2025.
  • The last three reported values for Raw Materials were $383.3 million (Q4 2025), $367.9 million (Q4 2024), and $389.3 million (Q4 2023) per Business Quant data.